Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 20% IN WATER vs ISMOTIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Reduction of intracranial pressure and cerebral edema,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (as an adjunct),Treatment of dialysis disequilibrium syndrome,Management of oliguric phase of acute renal failure
Reduction of elevated intracranial pressure,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
0.25–1.5 hours (15–90 minutes) in patients with normal renal function. In oliguric or anuric patients, half-life is markedly prolonged, up to 36 hours, due to reduced clearance.
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Not metabolized; excreted unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Not significantly metabolized; primarily excreted unchanged by the kidneys.
Primarily renal excretion as unchanged drug. Over 90% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized in the liver; negligible biliary/fecal elimination.
Renal: 90-95% unchanged; biliary/fecal: <5%
Negligible (<5%); essentially unbound.
<10% (negligible), primarily albumin
Approximately 0.3–0.6 L/kg. Mannitol distributes primarily in extracellular fluid; does not cross cell membranes readily unless administered in large doses or under pathological conditions (e.g., disrupted blood-brain barrier). Increased Vd may indicate expanded extracellular volume.
0.5-0.7 L/kg; limited to extracellular fluid compartment
Intravenous: 100%. Oral: Not applicable; not administered orally due to poor absorption and osmotic diarrhea. Other routes (e.g., subcutaneous or intramuscular) are not clinically relevant.
Oral: 60-70% (first-pass metabolism); Intravenous: 100%
Contraindicated in anuria or severe renal impairment (Cr Cl < 30 m L/min). Use with caution if Cr Cl < 50 m L/min; monitor serum osmolality and urine output. No specific dose adjustment guidelines exist; consider alternative therapy.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12 hours; GFR <10 m L/min: administer every 24 hours.
No specific adjustment required for hepatic impairment. Use with caution in severe liver disease due to risk of fluid overload.
No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Avoid in severe hepatic impairment (Child-Pugh C) due to risk of hepatic encephalopathy.
For reduction of intracranial pressure: 0.25-1 g/kg (1.25-5 m L/kg of 20% solution) intravenously over 30-60 minutes, repeated every 6-8 hours as needed. Maximum dose: 2 g/kg/day.
25-50 mg/kg orally every 6-8 hours, maximum 2 g/dose; or 25-50 mg/kg intravenously over 5-10 minutes every 6-8 hours, maximum 2 g/dose.
Start at lower end of dosing range (0.5 g/kg) due to increased risk of renal impairment and hypovolemia. Monitor serum electrolytes, osmolality, and renal function closely. Avoid in patients with significant cardiovascular disease.
Initiate at low end of dosing range (1 g every 8 hours) due to age-related renal function decline; adjust based on creatinine clearance.
No FDA boxed warning.
None.
Risk of pulmonary edema or congestive heart failure due to volume expansion,May cause electrolyte imbalance (e.g., hyponatremia, hyperkalemia) and dehydration,Monitor renal function; contraindicated in anuria or severe renal impairment,May increase intracranial pressure rebound effect,Use with caution in patients with severe hypovolemia or electrolyte disorders,Intravenous administration requires careful monitoring of fluid and electrolyte status
Monitor renal function and serum electrolytes,Avoid in patients with anuria or severe renal impairment,Risk of pulmonary edema, heart failure, and electrolyte disturbances
Anuria due to severe renal disease,Severe pulmonary congestion or pulmonary edema,Severe dehydration,Intracranial hemorrhage (unless during craniotomy) or active intracranial bleeding,Hypersensitivity to mannitol or any component of the formulation
Anuria,Severe renal failure,Congestive heart failure,Active intracranial bleeding (except during craniotomy),Hypovolemia
No significant food interactions. However, patients on this therapy often have restricted fluid and electrolyte intake; follow prescribed dietary restrictions, especially regarding sodium and fluid intake, as directed by the healthcare team.
Avoid high-tyramine foods (aged cheeses, cured meats, soy products) as hydralazine may increase tyramine sensitivity? No significant specific food interactions for isosorbide dinitrate/hydralazine. However, limit high-salt foods to manage heart failure. Avoid alcohol due to additive hypotensive effects.
Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretical risk of fetal osmotic shifts, but no well-controlled studies exist. In the second and third trimesters, use may cause fetal dehydration and electrolyte disturbances. Due to its limited indications in pregnancy (e.g., for elevated intracranial pressure), the risk-benefit must be carefully evaluated. Mannitol is assigned to FDA Pregnancy Category C.
No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fetal toxicity at doses 35 times the maximum human dose. First trimester: unknown risk, avoid unless clearly needed. Second and third trimesters: risk of maternal hypotension and reduced placental perfusion; use only if potential benefit justifies risk. Should be used with caution near term due to risk of neonatal hypotension.
It is unknown if mannitol is excreted in human milk. Given its high molecular weight and low lipid solubility, excretion is likely minimal but not confirmed. Caution is advised; use only if clearly needed. M/P ratio is not available.
Isosorbide dinitrate is excreted in human breast milk; clinical significance unknown. M/P ratio not reported. Caution is advised; consider temporary discontinuation of breastfeeding during therapy.
Pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may require dose adjustments. However, mannitol dosing is titrated to effect (e.g., urine output, serum osmolality). Pregnancy may reduce the duration of action. Monitor clinical response more frequently and adjust dose as needed to maintain desired osmolality and avoid toxicity.
Pregnancy may alter pharmacokinetics: increased plasma volume and renal clearance may reduce drug concentrations. However, no specific dose adjustments are recommended; titrate based on clinical response and tolerability. Start at lowest effective dose, increase cautiously. Avoid rapid dose escalation. Consider lower doses in third trimester due to increased sensitivity to vasodilation.
Monitor serum osmolarity and sodium levels closely; risk of hypematremia and hyperosmolality, especially in renal impairment. Use with caution in patients with congestive heart failure or pulmonary congestion. Administer via central line to avoid phlebitis. In acute renal failure, a test dose of 0.2 g/kg over 3-5 minutes may be given; if urine flow increases > 40 m L/h, full therapy can be initiated. Taper abruptly to avoid rebound intracranial hypertension. Contraindicated in anuria, intracranial hemorrhage, severe dehydration, and glucose intolerance (use with caution in diabetics).
ISOMOTIC (isosorbide dinitrate/hydralazine) is a fixed-dose combination for heart failure in self-identified Black patients. Monitor for hypotension, headache, and dizziness. Avoid use with PDE-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Titrate gradually to target dose to minimize adverse effects. May cause drug-induced lupus-like syndrome or peripheral neuropathy with hydralazine; consider slow acetylator phenotype risk.
This medication may cause you to urinate frequently; it is used to reduce brain swelling or to promote urine output.,You may experience headache, nausea, blurred vision, or thirst; report these to your healthcare provider.,Your fluid intake and output, as well as blood tests (electrolytes, kidney function), will be monitored closely.,Do not stop taking this medication abruptly without consulting your doctor; sudden withdrawal may worsen your condition.,Inform your doctor if you have heart disease, kidney disease, or diabetes.,This medication is given intravenously, usually in a hospital setting.
Take this medication exactly as prescribed to control your heart failure symptoms.,Do not take erectile dysfunction medicines (like sildenafil, tadalafil) while on this drug, as it can cause a dangerous drop in blood pressure.,You may experience headaches, dizziness, or lightheadedness when starting; these often improve over time. If severe, contact your doctor.,Avoid alcohol, which can worsen dizziness and low blood pressure.,Report any unexplained joint pain, fever, rash, or numbness/tingling in your hands or feet to your doctor immediately.,Swallow tablets whole; do not crush or chew.,Do not stop suddenly without consulting your doctor; abrupt discontinuation can worsen heart failure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 20% IN WATER vs ISMOTIC, answered by our medical review team.
OSMITROL 20% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.. ISMOTIC is a Osmotic Diuretic that works by Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 20% IN WATER and ISMOTIC depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 20% IN WATER is: 1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.. The standard adult dose of ISMOTIC is: 1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 20% IN WATER and ISMOTIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 20% IN WATER is classified as Category C. Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretica. ISMOTIC is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.